nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE7A—Ectoderm Differentiation—TFAP2C—testicular cancer	0.0513	0.0927	CbGpPWpGaD
Flavoxate—PDE8B—G alpha (s) signalling events—INSL3—testicular cancer	0.0511	0.0924	CbGpPWpGaD
Flavoxate—PDE8A—G alpha (s) signalling events—INSL3—testicular cancer	0.0511	0.0924	CbGpPWpGaD
Flavoxate—PDE8A—seminal vesicle—testicular cancer	0.0461	0.109	CbGeAlD
Flavoxate—PDE7B—G alpha (s) signalling events—INSL3—testicular cancer	0.0456	0.0823	CbGpPWpGaD
Flavoxate—PDE7A—G alpha (s) signalling events—INSL3—testicular cancer	0.0424	0.0765	CbGpPWpGaD
Flavoxate—PDE8B—gonad—testicular cancer	0.0371	0.0879	CbGeAlD
Flavoxate—PDE7B—testis—testicular cancer	0.0335	0.0796	CbGeAlD
Flavoxate—PDE4C—G alpha (s) signalling events—INSL3—testicular cancer	0.0276	0.0499	CbGpPWpGaD
Flavoxate—PDE8A—female gonad—testicular cancer	0.0271	0.0643	CbGeAlD
Flavoxate—PDE8B—testis—testicular cancer	0.0267	0.0634	CbGeAlD
Flavoxate—PDE4D—female gonad—testicular cancer	0.0245	0.0583	CbGeAlD
Flavoxate—PDE7B—lymph node—testicular cancer	0.0243	0.0577	CbGeAlD
Flavoxate—PDE4D—G alpha (s) signalling events—INSL3—testicular cancer	0.024	0.0434	CbGpPWpGaD
Flavoxate—PDE8A—testis—testicular cancer	0.024	0.057	CbGeAlD
Flavoxate—PDE4A—G alpha (s) signalling events—INSL3—testicular cancer	0.0229	0.0413	CbGpPWpGaD
Flavoxate—PDE4D—testis—testicular cancer	0.0218	0.0517	CbGeAlD
Flavoxate—PDE4A—female gonad—testicular cancer	0.0217	0.0515	CbGeAlD
Flavoxate—PDE4B—G alpha (s) signalling events—INSL3—testicular cancer	0.0212	0.0382	CbGpPWpGaD
Flavoxate—PDE8B—lymph node—testicular cancer	0.0194	0.0459	CbGeAlD
Flavoxate—PDE4A—testis—testicular cancer	0.0193	0.0457	CbGeAlD
Flavoxate—PDE8A—lymph node—testicular cancer	0.0174	0.0413	CbGeAlD
Flavoxate—PDE4B—gonad—testicular cancer	0.0159	0.0378	CbGeAlD
Flavoxate—PDE4D—lymph node—testicular cancer	0.0158	0.0374	CbGeAlD
Flavoxate—PDE4A—lymph node—testicular cancer	0.014	0.0331	CbGeAlD
Flavoxate—PDE4B—female gonad—testicular cancer	0.013	0.0307	CbGeAlD
Flavoxate—PDE4B—testis—testicular cancer	0.0115	0.0273	CbGeAlD
Flavoxate—PDE8B—GPCR downstream signaling—INSL3—testicular cancer	0.0105	0.019	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—INSL3—testicular cancer	0.0105	0.019	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—INSL3—testicular cancer	0.00952	0.0172	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—INSL3—testicular cancer	0.00952	0.0172	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—INSL3—testicular cancer	0.00935	0.0169	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—INSL3—testicular cancer	0.00869	0.0157	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—INSL3—testicular cancer	0.00849	0.0153	CbGpPWpGaD
Flavoxate—PDE4B—lymph node—testicular cancer	0.00833	0.0198	CbGeAlD
Flavoxate—PDE7A—Signaling by GPCR—INSL3—testicular cancer	0.00789	0.0143	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—INSL3—testicular cancer	0.00566	0.0102	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—INSL3—testicular cancer	0.00563	0.0102	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—INSL3—testicular cancer	0.00563	0.0102	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—INSL3—testicular cancer	0.00514	0.00929	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—INSL3—testicular cancer	0.00501	0.00906	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—INSL3—testicular cancer	0.00493	0.00891	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—INSL3—testicular cancer	0.00469	0.00848	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—INSL3—testicular cancer	0.00466	0.00843	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—INSL3—testicular cancer	0.00448	0.00809	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—INSL3—testicular cancer	0.00434	0.00785	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00433	0.00783	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00428	0.00773	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—INSL3—testicular cancer	0.00426	0.0077	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—INSL3—testicular cancer	0.00394	0.00713	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—INSL3—testicular cancer	0.0033	0.00596	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—INSL3—testicular cancer	0.00326	0.00589	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—INSL3—testicular cancer	0.00304	0.00549	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—INSL3—testicular cancer	0.00264	0.00478	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—INSL3—testicular cancer	0.00252	0.00455	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—INSL3—testicular cancer	0.00233	0.00421	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—INSL3—testicular cancer	0.00187	0.00337	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—INSL3—testicular cancer	0.00184	0.00333	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—H2AFZ—testicular cancer	0.0018	0.00325	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—H2AFZ—testicular cancer	0.0018	0.00325	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—STK11—testicular cancer	0.00179	0.00324	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—STK11—testicular cancer	0.00179	0.00324	CbGpPWpGaD
Flavoxate—CHRM1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.00172	0.0031	CbGpPWpGaD
Flavoxate—CHRM2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.0017	0.00306	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—INSL3—testicular cancer	0.00169	0.00306	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—INSL3—testicular cancer	0.00167	0.00302	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—KITLG—testicular cancer	0.00166	0.00299	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—KITLG—testicular cancer	0.00166	0.00299	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—H2AFZ—testicular cancer	0.00161	0.0029	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—STK11—testicular cancer	0.0016	0.00288	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—H2AFZ—testicular cancer	0.00149	0.0027	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—STK11—testicular cancer	0.00148	0.00268	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—KITLG—testicular cancer	0.00148	0.00267	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—KITLG—testicular cancer	0.00137	0.00248	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—FGFR3—testicular cancer	0.00123	0.00223	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—FGFR3—testicular cancer	0.00123	0.00223	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—KIT—testicular cancer	0.00113	0.00204	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—KIT—testicular cancer	0.00113	0.00204	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—FGFR3—testicular cancer	0.0011	0.00198	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—FGFR3—testicular cancer	0.00102	0.00184	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—KIT—testicular cancer	0.00101	0.00182	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—INSL3—testicular cancer	0.001	0.00181	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—INSL3—testicular cancer	0.000988	0.00178	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—H2AFZ—testicular cancer	0.000973	0.00176	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—STK11—testicular cancer	0.000967	0.00175	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—KIT—testicular cancer	0.000937	0.00169	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—KITLG—testicular cancer	0.000895	0.00162	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—H2AFZ—testicular cancer	0.000847	0.00153	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—STK11—testicular cancer	0.000842	0.00152	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—H2AFZ—testicular cancer	0.000806	0.00146	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—STK11—testicular cancer	0.000801	0.00145	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—KITLG—testicular cancer	0.000779	0.00141	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—H2AFZ—testicular cancer	0.000746	0.00135	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—STK11—testicular cancer	0.000741	0.00134	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—KITLG—testicular cancer	0.000741	0.00134	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—KITLG—testicular cancer	0.000686	0.00124	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—FGFR3—testicular cancer	0.000665	0.0012	CbGpPWpGaD
Flavoxate—Leukopenia—Chlorambucil—testicular cancer	0.000611	0.0242	CcSEcCtD
Flavoxate—PDE4C—Signaling Pathways—KIT—testicular cancer	0.000611	0.0011	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—FGFR3—testicular cancer	0.000579	0.00105	CbGpPWpGaD
Flavoxate—Vertigo—Vinblastine—testicular cancer	0.000562	0.0223	CcSEcCtD
Flavoxate—Confusional state—Chlorambucil—testicular cancer	0.000562	0.0223	CcSEcCtD
Flavoxate—Leukopenia—Vinblastine—testicular cancer	0.00056	0.0222	CcSEcCtD
Flavoxate—PDE4A—Signaling Pathways—FGFR3—testicular cancer	0.000551	0.000996	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—KIT—testicular cancer	0.000531	0.00096	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—FGFR3—testicular cancer	0.00051	0.000921	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—KIT—testicular cancer	0.000506	0.000914	CbGpPWpGaD
Flavoxate—Leukopenia—Bleomycin—testicular cancer	0.000473	0.0188	CcSEcCtD
Flavoxate—PDE4B—Signaling Pathways—KIT—testicular cancer	0.000468	0.000846	CbGpPWpGaD
Flavoxate—Feeling abnormal—Chlorambucil—testicular cancer	0.000459	0.0182	CcSEcCtD
Flavoxate—Urticaria—Chlorambucil—testicular cancer	0.000443	0.0175	CcSEcCtD
Flavoxate—Leukopenia—Dactinomycin—testicular cancer	0.000441	0.0175	CcSEcCtD
Flavoxate—Confusional state—Bleomycin—testicular cancer	0.000435	0.0172	CcSEcCtD
Flavoxate—Vision blurred—Ifosfamide—testicular cancer	0.000426	0.0169	CcSEcCtD
Flavoxate—Feeling abnormal—Vinblastine—testicular cancer	0.000421	0.0167	CcSEcCtD
Flavoxate—Vertigo—Ifosfamide—testicular cancer	0.000406	0.0161	CcSEcCtD
Flavoxate—Leukopenia—Ifosfamide—testicular cancer	0.000404	0.016	CcSEcCtD
Flavoxate—Palpitations—Ifosfamide—testicular cancer	0.000399	0.0158	CcSEcCtD
Flavoxate—Confusional state—Ifosfamide—testicular cancer	0.000372	0.0147	CcSEcCtD
Flavoxate—Vision blurred—Cisplatin—testicular cancer	0.000367	0.0145	CcSEcCtD
Flavoxate—Skin disorder—Ifosfamide—testicular cancer	0.000358	0.0142	CcSEcCtD
Flavoxate—Feeling abnormal—Bleomycin—testicular cancer	0.000355	0.0141	CcSEcCtD
Flavoxate—Vomiting—Chlorambucil—testicular cancer	0.000354	0.014	CcSEcCtD
Flavoxate—Leukopenia—Cisplatin—testicular cancer	0.000348	0.0138	CcSEcCtD
Flavoxate—Urticaria—Bleomycin—testicular cancer	0.000343	0.0136	CcSEcCtD
Flavoxate—Feeling abnormal—Dactinomycin—testicular cancer	0.000331	0.0131	CcSEcCtD
Flavoxate—Nausea—Chlorambucil—testicular cancer	0.000331	0.0131	CcSEcCtD
Flavoxate—Somnolence—Ifosfamide—testicular cancer	0.000328	0.013	CcSEcCtD
Flavoxate—Vomiting—Vinblastine—testicular cancer	0.000325	0.0129	CcSEcCtD
Flavoxate—Vertigo—Etoposide—testicular cancer	0.00032	0.0127	CcSEcCtD
Flavoxate—CHRM1—Signaling Pathways—H2AFZ—testicular cancer	0.00032	0.000579	CbGpPWpGaD
Flavoxate—Headache—Vinblastine—testicular cancer	0.00032	0.0127	CcSEcCtD
Flavoxate—Leukopenia—Etoposide—testicular cancer	0.000319	0.0127	CcSEcCtD
Flavoxate—CHRM1—Signaling Pathways—STK11—testicular cancer	0.000318	0.000575	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—H2AFZ—testicular cancer	0.000316	0.000571	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STK11—testicular cancer	0.000314	0.000568	CbGpPWpGaD
Flavoxate—Tachycardia—Cisplatin—testicular cancer	0.00031	0.0123	CcSEcCtD
Flavoxate—Skin disorder—Cisplatin—testicular cancer	0.000309	0.0122	CcSEcCtD
Flavoxate—Feeling abnormal—Ifosfamide—testicular cancer	0.000304	0.012	CcSEcCtD
Flavoxate—Eosinophilia—Methotrexate—testicular cancer	0.000304	0.012	CcSEcCtD
Flavoxate—Nausea—Vinblastine—testicular cancer	0.000303	0.012	CcSEcCtD
Flavoxate—CHRM1—Signaling Pathways—KITLG—testicular cancer	0.000295	0.000532	CbGpPWpGaD
Flavoxate—Confusional state—Etoposide—testicular cancer	0.000293	0.0116	CcSEcCtD
Flavoxate—Urticaria—Ifosfamide—testicular cancer	0.000293	0.0116	CcSEcCtD
Flavoxate—CHRM2—Signaling Pathways—KITLG—testicular cancer	0.000291	0.000526	CbGpPWpGaD
Flavoxate—Tachycardia—Etoposide—testicular cancer	0.000284	0.0113	CcSEcCtD
Flavoxate—Eosinophilia—Epirubicin—testicular cancer	0.000284	0.0113	CcSEcCtD
Flavoxate—Skin disorder—Etoposide—testicular cancer	0.000283	0.0112	CcSEcCtD
Flavoxate—Vomiting—Bleomycin—testicular cancer	0.000274	0.0109	CcSEcCtD
Flavoxate—Drowsiness—Methotrexate—testicular cancer	0.000273	0.0108	CcSEcCtD
Flavoxate—Eosinophilia—Doxorubicin—testicular cancer	0.000263	0.0104	CcSEcCtD
Flavoxate—Feeling abnormal—Cisplatin—testicular cancer	0.000262	0.0104	CcSEcCtD
Flavoxate—Somnolence—Etoposide—testicular cancer	0.000259	0.0103	CcSEcCtD
Flavoxate—Nausea—Bleomycin—testicular cancer	0.000256	0.0102	CcSEcCtD
Flavoxate—Drowsiness—Epirubicin—testicular cancer	0.000256	0.0101	CcSEcCtD
Flavoxate—Vomiting—Dactinomycin—testicular cancer	0.000256	0.0101	CcSEcCtD
Flavoxate—Feeling abnormal—Etoposide—testicular cancer	0.00024	0.00951	CcSEcCtD
Flavoxate—Nausea—Dactinomycin—testicular cancer	0.000239	0.00947	CcSEcCtD
Flavoxate—Drowsiness—Doxorubicin—testicular cancer	0.000237	0.00938	CcSEcCtD
Flavoxate—Vomiting—Ifosfamide—testicular cancer	0.000234	0.00929	CcSEcCtD
Flavoxate—Urticaria—Etoposide—testicular cancer	0.000231	0.00917	CcSEcCtD
Flavoxate—CHRM1—Signaling Pathways—FGFR3—testicular cancer	0.000219	0.000396	CbGpPWpGaD
Flavoxate—Nausea—Ifosfamide—testicular cancer	0.000219	0.00868	CcSEcCtD
Flavoxate—CHRM2—Signaling Pathways—FGFR3—testicular cancer	0.000216	0.000391	CbGpPWpGaD
Flavoxate—Vomiting—Cisplatin—testicular cancer	0.000202	0.00801	CcSEcCtD
Flavoxate—Vision blurred—Methotrexate—testicular cancer	0.000201	0.00798	CcSEcCtD
Flavoxate—CHRM1—Signaling Pathways—KIT—testicular cancer	0.000201	0.000363	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KIT—testicular cancer	0.000198	0.000359	CbGpPWpGaD
Flavoxate—Tension—Epirubicin—testicular cancer	0.000196	0.00778	CcSEcCtD
Flavoxate—Nervousness—Epirubicin—testicular cancer	0.000194	0.0077	CcSEcCtD
Flavoxate—Vertigo—Methotrexate—testicular cancer	0.000192	0.00761	CcSEcCtD
Flavoxate—Leukopenia—Methotrexate—testicular cancer	0.000191	0.00758	CcSEcCtD
Flavoxate—Nausea—Cisplatin—testicular cancer	0.000189	0.00748	CcSEcCtD
Flavoxate—Vision blurred—Epirubicin—testicular cancer	0.000188	0.00747	CcSEcCtD
Flavoxate—Vomiting—Etoposide—testicular cancer	0.000185	0.00734	CcSEcCtD
Flavoxate—Headache—Etoposide—testicular cancer	0.000182	0.00723	CcSEcCtD
Flavoxate—Tension—Doxorubicin—testicular cancer	0.000182	0.0072	CcSEcCtD
Flavoxate—Nervousness—Doxorubicin—testicular cancer	0.00018	0.00712	CcSEcCtD
Flavoxate—Vertigo—Epirubicin—testicular cancer	0.00018	0.00712	CcSEcCtD
Flavoxate—Leukopenia—Epirubicin—testicular cancer	0.000179	0.00709	CcSEcCtD
Flavoxate—Palpitations—Epirubicin—testicular cancer	0.000177	0.007	CcSEcCtD
Flavoxate—Confusional state—Methotrexate—testicular cancer	0.000176	0.00697	CcSEcCtD
Flavoxate—Vision blurred—Doxorubicin—testicular cancer	0.000174	0.00691	CcSEcCtD
Flavoxate—Nausea—Etoposide—testicular cancer	0.000173	0.00685	CcSEcCtD
Flavoxate—Skin disorder—Methotrexate—testicular cancer	0.000169	0.00671	CcSEcCtD
Flavoxate—Dry mouth—Epirubicin—testicular cancer	0.000166	0.0066	CcSEcCtD
Flavoxate—Vertigo—Doxorubicin—testicular cancer	0.000166	0.00659	CcSEcCtD
Flavoxate—Leukopenia—Doxorubicin—testicular cancer	0.000166	0.00656	CcSEcCtD
Flavoxate—Confusional state—Epirubicin—testicular cancer	0.000164	0.00652	CcSEcCtD
Flavoxate—Palpitations—Doxorubicin—testicular cancer	0.000163	0.00648	CcSEcCtD
Flavoxate—Tachycardia—Epirubicin—testicular cancer	0.000159	0.00631	CcSEcCtD
Flavoxate—Skin disorder—Epirubicin—testicular cancer	0.000158	0.00628	CcSEcCtD
Flavoxate—Somnolence—Methotrexate—testicular cancer	0.000155	0.00614	CcSEcCtD
Flavoxate—Dry mouth—Doxorubicin—testicular cancer	0.000154	0.00611	CcSEcCtD
Flavoxate—Confusional state—Doxorubicin—testicular cancer	0.000152	0.00603	CcSEcCtD
Flavoxate—Tachycardia—Doxorubicin—testicular cancer	0.000147	0.00584	CcSEcCtD
Flavoxate—Skin disorder—Doxorubicin—testicular cancer	0.000147	0.00581	CcSEcCtD
Flavoxate—Somnolence—Epirubicin—testicular cancer	0.000145	0.00575	CcSEcCtD
Flavoxate—Feeling abnormal—Methotrexate—testicular cancer	0.000144	0.0057	CcSEcCtD
Flavoxate—Urticaria—Methotrexate—testicular cancer	0.000138	0.00549	CcSEcCtD
Flavoxate—Feeling abnormal—Epirubicin—testicular cancer	0.000134	0.00533	CcSEcCtD
Flavoxate—Somnolence—Doxorubicin—testicular cancer	0.000134	0.00532	CcSEcCtD
Flavoxate—Urticaria—Epirubicin—testicular cancer	0.00013	0.00514	CcSEcCtD
Flavoxate—Feeling abnormal—Doxorubicin—testicular cancer	0.000124	0.00493	CcSEcCtD
Flavoxate—Urticaria—Doxorubicin—testicular cancer	0.00012	0.00475	CcSEcCtD
Flavoxate—Vomiting—Methotrexate—testicular cancer	0.000111	0.00439	CcSEcCtD
Flavoxate—Headache—Methotrexate—testicular cancer	0.000109	0.00433	CcSEcCtD
Flavoxate—Vomiting—Epirubicin—testicular cancer	0.000104	0.00411	CcSEcCtD
Flavoxate—Nausea—Methotrexate—testicular cancer	0.000104	0.00411	CcSEcCtD
Flavoxate—Headache—Epirubicin—testicular cancer	0.000102	0.00405	CcSEcCtD
Flavoxate—Nausea—Epirubicin—testicular cancer	9.69e-05	0.00384	CcSEcCtD
Flavoxate—Vomiting—Doxorubicin—testicular cancer	9.6e-05	0.00381	CcSEcCtD
Flavoxate—Headache—Doxorubicin—testicular cancer	9.46e-05	0.00375	CcSEcCtD
Flavoxate—Nausea—Doxorubicin—testicular cancer	8.97e-05	0.00356	CcSEcCtD
